AD lymphocytes were also incubated with 0.1 μM Aβ42 to maintain experimenter blinding and to show that FLNA hyperphosphorylation in AD lymphocytes is mediated by endogenous Aβ42. Oral simufilam given to AD subjects in the clinical trial reduced levels of pS2152FLNA at Day 28 (Figures 5C, D; p < 0.001) and increased FLNA—PTEN linkage in lymphocytes at both Day 14 and Day 28 (p < 0.01). The gene discussed is PTEN; the disease is Alzheimer disease.